 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Antigenics Inc.
 |
Antigenics Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Biotechs turn to convertibles as IPOs dry up Jul 15 2001 08:46 AM PDT
Antigenics to offer $50 mln in preferred stock Jul 13 2001 04:28 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Cancer and other diseases had better beware -- Antigenics is packing heat. The biotech firm is developing heat shock proteins, which studies have shown are related to the immune system's response to disease. Its lead drug candidate, Oncophage, is in development for non-Hodgkin's lymphoma and sarcoma, as well as renal, pancreatic, and other cancers. Working on the theory that each person's cancer has a unique signature, the patient-specific vaccine is derived from the cancerous tumor after it has been surgically removed. Subsidiary Aquila Biopharmaceuticals also focuses on regulating the immune system to treat cancer and infectious diseases. Chairman and CEO Garo Armen owns more than 40% of the firm.
COMPETITION |
 |
Cell Genesys, Inc. (CEGE)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.40
1-Yr. Sales Growth: 300.0%
Employees: 162
Revenue per employee: $2,469.14
KEY PEOPLE |
 |
Garo H. Armen
CEO
Scott Murphy
CFO
CONTACT INFO |
 |
630 Fifth Ave.
New York, NY 10111
US
Phone: 212-332-4774
Fax: 212-332-4778
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |